QIAGEN Reports Results for Second Quarter and First Half of 2017

Thursday, July 27, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

VENLO, Netherlands, July 27, 2017 /PRNewswire/ --

  • Strong Q2 2017 results reaffirm QIAGEN on track to achieve full-year goals
    : 
  • Net sales $349.0 million (+4% actual); adjusted net sales $349.6 million (+5% actual, +
    7% CER vs. +5-6% CER guidance) 
  • EPS $0.06; adjusted EPS $0.25 ($0.25 CER), adjusted EPS excluding restructuring charge $0.30 ($0.30 CER vs. $0.28-0.29 CER guidance) 
  • H1 free cash flow of $91.6 million impacted by $30.8 million for restructuring 
  • Sample to Insight portfolio momentum with expansion of QuantiFERON latent TB test, Personalized Healthcare, NGS portfolio and QIAsymphony platform 
  • QIAGEN upgrades 2017 adjusted sales outlook after solid H1, now expects 7% CER growth; keeps adjusted EPS target before restructuring of $1.25-1.27 CER 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2017, delivering on goals for improvements in net sales and adjusted earnings.

"QIAGEN's performance for the second quarter of 2017 further strengthens our confidence in achieving our full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share, as our differentiated portfolio of Sample to Insight molecular testing solutions gains momentum," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-07-27-q2results

www.twitter.com/qiagen 

www.facebook.com/QIAGEN 

Download the QIAGEN Investor Relations App

Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8

Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de

Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: [email protected] ir.qiagen.com Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: [email protected] pr.qiagen.com

SOURCE QIAGEN N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store